0001209191-23-019656.txt : 20230317 0001209191-23-019656.hdr.sgml : 20230317 20230317163353 ACCESSION NUMBER: 0001209191-23-019656 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230315 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nash Huw M. CENTRAL INDEX KEY: 0001780085 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38938 FILM NUMBER: 23743134 MAIL ADDRESS: STREET 1: C/O STOKE THERAPEUTICS, INC. STREET 2: 45 WIGGINS AVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stoke Therapeutics, Inc. CENTRAL INDEX KEY: 0001623526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471144582 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-430-8200 MAIL ADDRESS: STREET 1: 45 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141028 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-15 0 0001623526 Stoke Therapeutics, Inc. STOK 0001780085 Nash Huw M. C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 0 1 0 0 COO & CBO Employee Stock Option (Right to Buy) 9.15 2023-03-15 4 A 0 78600 0.00 A 2033-03-14 Common Stock 78600 78600 D Restricted Stock Unit (RSU) 2023-03-15 4 A 0 52400 0.00 A 2027-03-15 Common Stock 52400 52400 D The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. /s/ Stephen Tulipano, Attorney-in-Fact 2023-03-17